We're thrilled to announce that Verinetics has successfully raised $135,000 in its latest round of funding. This investment marks a significant milestone for the company, dedicated to expanding the reach of medications used to treat opioid use disorder. Verinetics’ innovative approach focuses on enhancing patient safety and building trust between patients and healthcare providers through its advanced technology. At the core of this progress is the Verinetics DispenSecur™ system—a Class I Medical Device that is FDA-listed for distribution within the United States. The system is designed explicitly for improved monitoring and control over medications, offering a sophisticated solution for managing treatment regimens for opioid use disorder and other risky medications susceptible to abuse or misuse.
The newly raised funds will accelerate the continued development and widespread implementation of DispenSecur™, ensuring that its benefits reach more patients who need them. By providing alerts and controlled patient access according to dosing schedules pre-determined by healthcare professionals, the device acts as a crucial safeguard—helping to minimize potential misuse while maintaining the flexibility required for effective pain management and addiction treatment. In addition to ongoing R&D efforts, the funding will also be channeled towards expanding market outreach, refining product features based on user feedback, and ensuring a robust distribution network that spans key regions across the nation.
Verinetics is proud to lead a transformative charge in the healthcare arena by prioritizing both patient wellness and provider trust. The company remains committed to leveraging innovative technology to confront one of today’s most pressing public health challenges, ensuring that lifesaving medications are not only accessible, but also responsibly managed for the benefit of all.
